Enfusion . Quarterly Balance Sheets Chart
Quarterly
|
Annual
Enfusion . Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||
| current assets: | ||||||||||||||
| cash and cash equivalents | 54,480,000 | 48,299,000 | 34,447,000 | 32,894,000 | 35,604,000 | 31,652,000 | 27,771,000 | 54,598,000 | 62,545,000 | 63,543,000 | ||||
| accounts receivable | 31,988,000 | 32,173,000 | 33,672,000 | 30,932,000 | 28,069,000 | 24,855,000 | 25,170,000 | 24,356,000 | 25,855,000 | 28,992,000 | 28,771,000 | 23,410,000 | 18,223,000 | |
| prepaid expenses | 5,342,000 | 3,576,000 | 4,475,000 | 5,420,000 | 5,009,000 | 4,079,000 | 4,967,000 | 5,600,000 | 6,105,000 | 2,605,000 | 3,634,000 | 5,458,000 | ||
| other current assets | 1,711,000 | 1,388,000 | 1,573,000 | 1,677,000 | 1,170,000 | 1,459,000 | 1,718,000 | 2,093,000 | 2,303,000 | 888,000 | 1,287,000 | 1,332,000 | ||
| total current assets | 93,521,000 | 85,436,000 | 74,167,000 | 70,923,000 | 69,852,000 | 62,045,000 | 59,626,000 | 86,647,000 | 96,808,000 | 96,028,000 | 90,251,000 | 86,406,000 | 89,678,000 | |
| notes receivable | 3,000,000 | 3,000,000 | 3,000,000 | |||||||||||
| property, equipment, and software | 20,963,000 | 20,513,000 | 19,672,000 | 18,851,000 | 18,314,000 | |||||||||
| right-of-use-assets | 18,062,000 | 18,926,000 | 16,054,000 | 14,151,000 | 14,304,000 | 15,734,000 | 12,388,000 | 13,438,000 | ||||||
| other assets | 7,715,000 | 7,065,000 | 7,197,000 | 7,038,000 | 6,502,000 | 5,825,000 | 4,532,000 | 4,529,000 | 4,484,000 | 4,151,000 | 3,783,000 | 3,499,000 | 3,356,000 | |
| total assets | 143,261,000 | 134,940,000 | 120,090,000 | 110,963,000 | 108,972,000 | 101,740,000 | 94,053,000 | 121,493,000 | 123,783,000 | 115,602,000 | 110,127,000 | 104,951,000 | 106,085,000 | 1 |
| | ||||||||||||||
| liabilities and stockholders’ equity | ||||||||||||||
| current liabilities: | ||||||||||||||
| accounts payable | 867,000 | 1,175,000 | 816,000 | 3,364,000 | 2,212,000 | 1,341,000 | 868,000 | 1,290,000 | 1,685,000 | 1,185,000 | 879,000 | 1,189,000 | 2,528,000 | |
| accrued expenses and other current liabilities | 20,393,000 | 16,460,000 | 11,862,000 | 9,513,000 | 13,841,000 | 10,629,000 | 8,129,000 | 7,403,000 | 11,665,000 | 10,804,000 | 8,963,000 | 6,557,000 | 5,578,000 | |
| current portion of lease liabilities | 6,076,000 | 5,935,000 | 5,194,000 | 4,529,000 | 4,256,000 | 4,403,000 | 4,761,000 | 5,013,000 | 4,030,000 | |||||
| total current liabilities | 27,336,000 | 23,570,000 | 17,872,000 | 17,406,000 | 20,309,000 | 16,373,000 | 13,758,000 | 13,706,000 | 17,380,000 | 11,989,000 | 9,842,000 | 7,746,000 | 8,106,000 | |
| lease liabilities, net of current portion | 14,236,000 | 15,193,000 | 12,803,000 | 10,931,000 | 11,181,000 | 12,090,000 | 8,052,000 | 8,642,000 | 2,959,000 | |||||
| other non-current liabilities | 2,150,000 | |||||||||||||
| total liabilities | 43,722,000 | 38,763,000 | 30,675,000 | 28,337,000 | 31,490,000 | 28,463,000 | 21,810,000 | 22,348,000 | 20,339,000 | 12,432,000 | 10,321,000 | 8,243,000 | 8,644,000 | |
| commitment and contingencies | ||||||||||||||
| stockholders’ equity: | ||||||||||||||
| preferred stock, 0.001 par value; 100,000 shares authorized, no shares issued and outstanding as of december 31, 2024 and december 31, 2023, respectively | ||||||||||||||
| class a common stock | 95,000 | 93,000 | 92,000 | 90,000 | 88,000 | 88,000 | 82,000 | 74,000 | 71,000 | 67,000 | 67,000 | 66,000 | 66,000 | |
| class b common stock | 34,000 | 35,000 | 36,000 | 38,000 | 39,000 | 39,000 | 41,000 | 41,000 | 43,000 | 46,000 | 46,000 | 47,000 | 47,000 | |
| additional paid-in capital | 243,935,000 | 240,224,000 | 236,327,000 | 231,881,000 | 226,877,000 | 224,710,000 | 223,766,000 | 240,075,000 | 244,260,000 | 241,045,000 | 240,501,000 | 233,607,000 | 226,717,000 | |
| accumulated deficit | -170,109,000 | -170,230,000 | -171,645,000 | -173,471,000 | -172,932,000 | -173,555,000 | -175,383,000 | -176,012,000 | -178,863,000 | -179,357,000 | -180,896,000 | -178,474,000 | -171,209,000 | |
| accumulated other comprehensive loss | -734,000 | -199,000 | -509,000 | -484,000 | -406,000 | -548,000 | -378,000 | -473,000 | -504,000 | -672,000 | -582,000 | -375,000 | -325,000 | |
| total stockholders’ equity attributable to enfusion, inc. | 73,221,000 | 69,923,000 | 64,301,000 | 58,054,000 | 53,666,000 | 50,734,000 | 48,128,000 | 63,705,000 | 65,007,000 | 61,129,000 | 59,136,000 | 54,871,000 | ||
| non-controlling interests | 26,318,000 | 26,254,000 | 25,114,000 | 24,572,000 | 23,816,000 | 22,543,000 | 24,115,000 | 35,440,000 | 38,437,000 | 42,041,000 | 40,670,000 | 41,837,000 | 42,145,000 | |
| total stockholders’ equity | 99,539,000 | 96,177,000 | 89,415,000 | 82,626,000 | 77,482,000 | 73,277,000 | ||||||||
| total liabilities and stockholders’ equity | 143,261,000 | 134,940,000 | 120,090,000 | 110,963,000 | 108,972,000 | 101,740,000 | ||||||||
| preferred stock, 0.001 par value; 100,000 shares authorized, no shares issued and outstanding as of september 30, 2024 and december 31, 2023, respectively | ||||||||||||||
| preferred stock, 0.001 par value; 100,000 shares authorized, no shares issued and outstanding as of june 30, 2024 and december 31, 2023, respectively | ||||||||||||||
| preferred stock, 0.001 par value; 100,000 shares authorized, no shares issued and outstanding as of march 31, 2024 and december 31, 2023, respectively | ||||||||||||||
| preferred stock, 0.001 par value; 100,000 shares authorized, no shares issued and outstanding as of december 31, 2023 and december 31, 2022, respectively | ||||||||||||||
| property and equipment | 18,136,000 | 17,507,000 | 16,879,000 | 15,759,000 | 15,423,000 | 16,093,000 | 15,046,000 | 13,051,000 | ||||||
| preferred stock, 0.001 par value; 100,000 shares authorized, no shares issued and outstanding as of september 30, 2023 and december 31, 2022, respectively | ||||||||||||||
| liabilities and stockholders' equity | ||||||||||||||
| stockholders' equity: | ||||||||||||||
| preferred stock, 0.001 par value; 100,000 shares authorized, no shares issued and outstanding as of june 30, 2023 and december 31, 2022, respectively | ||||||||||||||
| total stockholders' equity | 72,243,000 | 99,145,000 | 103,444,000 | 103,170,000 | 99,806,000 | 96,708,000 | ||||||||
| total liabilities and stockholders' equity | 94,053,000 | 121,493,000 | 123,783,000 | 115,602,000 | 110,127,000 | 104,951,000 | ||||||||
| right-of-use assets | 6,732,000 | |||||||||||||
| other liabilities | 443,000 | 479,000 | 497,000 | 538,000 | ||||||||||
| cash | 56,559,000 | 56,206,000 | 64,365,000 | 1 | ||||||||||
| commitments and contingencies | ||||||||||||||
| prepaid expenses and other current assets | 7,090,000 | |||||||||||||
| liabilities, preferred units, stockholders' equity and members’ deficit | ||||||||||||||
| current portion of long-term debt | ||||||||||||||
| long-term debt, net of discount and issuance costs | ||||||||||||||
| preferred units: | ||||||||||||||
| class c-1 units, no par value, 28.777 units issued and outstanding as of december 31, 2020 | ||||||||||||||
| class c-2 units, no par value, 12.219 units issued and outstanding as of december 31, 2020 | ||||||||||||||
| class d units, no par value, 12.778 units issued and outstanding as of december 31, 2020 | ||||||||||||||
| total preferred units | ||||||||||||||
| stockholders' equity/members’ deficit: | ||||||||||||||
| members' deficit, no par value, 47.968 units issued and outstanding as of december 31, 2020 | ||||||||||||||
| preferred stock, par value 0.001 per share, 100,000,000 shares authorized, no shares issued and outstanding as of december 31, 2021 | ||||||||||||||
| total stockholders’ equity attributable to enfusion, inc. /members’ deficit | 55,296,000 | |||||||||||||
| total stockholders' equity/ members’ deficit | 97,441,000 | |||||||||||||
| total liabilities, preferred units and stockholders’ equity/members’ deficit | 106,085,000 | |||||||||||||
| stockholder's equity | ||||||||||||||
| common stock | 1 | |||||||||||||
| total stockholder's equity | 1 | |||||||||||||
| ● |
We provide you with 20 years of balance sheets for Enfusion . stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Enfusion .. Explore the full financial landscape of Enfusion . stock with our expertly curated balance sheets.
The information provided in this report about Enfusion . stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.